» Authors » Cecile Pochon

Cecile Pochon

Explore the profile of Cecile Pochon including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 48
Citations 248
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Petitpain N, Prontskus V, Gauthier M, Loutterbach L, Pochon C, Dalle J, et al.
Ann Pharm Fr . 2025 Mar; PMID: 40023491
Advanced therapy medicinal products (ATMPs) are playing an increasingly important role in therapeutics, and sometimes represent the only hope of improving or even curing some pathologies. Because of their biological...
3.
Roussel A, Leglise C, Rialland F, Duplan M, Falaque F, Boulanger C, et al.
Bull Cancer . 2024 Dec; 112(2):208-224. PMID: 39706725
Children and adolescents who are being treated or have been treated for acute leukemia have a secondary immunodeficiency linked to chemotherapy, resulting in an increased risk of infections. Some of...
4.
Danhardt L, Wiedemann A, Michel G, Dalle J, Rialland F, Renard C, et al.
EJHaem . 2024 Dec; 5(6):1295-1300. PMID: 39691249
Context: Mucopolysaccharidosis (MPS) requires urgent treatment to prevent neurological damage. While gene therapy holds promise for effectively treating these diseases with minimal toxicity, access remains limited for most patients. Consequently,...
5.
Le Calvez B, Jullien M, Dalle J, Renard C, Jubert C, Sterin A, et al.
Hemasphere . 2024 Jul; 8(7):e120. PMID: 38978638
For most patients with childhood myelodysplastic syndrome (cMDS), allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option. In the case of increased blasts (cMDS-IB), the benefit of pretransplant...
6.
Renard C, Corbel A, Paillard C, Pochon C, Schneider P, Simon N, et al.
Bull Cancer . 2024 Jun; 112(1S):S135-S145. PMID: 38926053
Treatment of pediatric high-risk acute myeloid leukemia (AML), defined either on molecular or cytogenetic features, relies on bone marrow transplant after cytologic remission. However, relapse remains the first post-transplant cause...
7.
Leroyer E, Petitpain N, Morisset S, Neven B, Castelle M, Winter S, et al.
Hemasphere . 2024 Mar; 8(1):e40. PMID: 38434523
No abstract available.
8.
Meyran D, Arfeuille C, Chevret S, Neven Q, Caye-Eude A, Lainey E, et al.
Haematologica . 2024 Feb; 109(9):2908-2919. PMID: 38385260
Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric myeloproliferative neoplasm requiring hematopoietic stem cell transplantation (HSCT) in most cases. We retrospectively analyzed 119 JMML patients who underwent first allogeneic HSCT...
9.
Pochon C, Lubnau M, Pagliuca S
Medicina (Kaunas) . 2023 Nov; 59(11). PMID: 38003941
During the last few years, the therapeutic landscape of idiopathic aplastic anemia (IAA) has been profoundly revolutionized by the increased use of alternative transplant procedures, such that today hematopoietic cell...
10.
Pochon C, Laroye C, Kimmoun A, Reppel L, Dhuyser A, Rousseau H, et al.
Front Med (Lausanne) . 2023 Sep; 10:1224865. PMID: 37706025
Background: The COVID-19 pandemic caused a wave of acute respiratory distress syndrome (ARDS) with a high in-hospital mortality, especially in patients requiring invasive mechanical ventilation. Wharton Jelly-derived Mesenchymal Stromal Cells...